AbbVie's VENCLYXTO/VENCLEXTA (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced new findings demonstrating sustained long-term safety and efficacy of VENCLYXTO/VENCLEXTA-based combination therapies in patients with previously untreated CLL with co-existing conditions, as well as R/R CLL. The results are being presented at the EHA Annual Congress in Frankfurt, Germany.
June 09, 2023 | 7:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's VENCLYXTO/VENCLEXTA demonstrates sustained long-term safety and efficacy in CLL patients, potentially boosting the company's stock price.
The positive results of AbbVie's VENCLYXTO/VENCLEXTA in CLL patients indicate the potential for increased sales and revenue for the company. This news may attract more investors, leading to a potential increase in the stock price of AbbVie (ABBV) in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100